{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"Any grade 4 hematological toxicity or grade 3-5 organ toxicity 30 days following the last dose of study drug.","groups":[{"description":"Patients receive lenalidomide PO QD on days 1-21 of courses 1, 3, 5 and 7. Beginning 1-3 days after the last dose of lenalidomide patients receive one dose of ipilimumab IV over 90 minutes of courses 2, 4, 6 and 8. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.\n\nIpilimumab: Given IV\n\nLenalidomide: Given PO","id":"OG000","title":"Autologous -Treatment (Lenalidomide and Ipilimumab)"},{"description":"Patients receive lenalidomide PO QD on days 1-21 of courses 1, 3, 5 and 7. Beginning 1-3 days after the last dose of lenalidomide patients receive one dose of ipilimumab IV over 90 minutes of courses 2, 4, 6 and 8. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.\n\nIpilimumab: Given IV\n\nLenalidomide: Given PO","id":"OG001","title":"Allogeneic - Treatment (Lenalidomide and Ipilimumab)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 30 days following the last dose of study drugs","title":"Number of Participants Experienced Severe Toxicity From Lenalidomide and Ipilimumab Post Transplant","type":"PRIMARY","unitOfMeasure":"Participants"}